TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04289103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inolimomab (Leukotac)
Description: * Patient screening phase - Patients diagnosed with aGvHD will be identified. Only patients with SR-aGvHD will be finally included in the study.~* Treatment phase - Leukotac will be given up to D28~* Primary Follow-up phase - Patient's response (CR and PR) will be evaluated at D29 post inclusion. Patients will then be followed for survival, long-term safety and chronic GvHD occurrence during 6 months after inclusion.
Study: NCT05908383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMDTC for injection
Description: GMDTC for injection with a specification of 0.5g/vial, 250mg,500mg,850mg,1200mg,1600mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
Study: NCT04874909

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample of 15ml max by subject (case, related individual, control) once time:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample of 15ml max by subject (case, related individual, control) once time:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample of 15ml max by subject (case, related individual, control) once time:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample of 15ml max by subject (case, related individual, control) once time:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sample
Description: Urine sample (500 ml) once time

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sample
Description: Urine sample (500 ml) once time

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sample
Description: Urine sample (500 ml) once time

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sample
Description: Urine sample (500 ml) once time
Study: NCT05731024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: close-loop synchronization controller with SPONT mode
Description: One-hour period where the pressure support of spontaneous breath will be automatically titrated based on pressure and flow waveform analysis obtained from the patient.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional synchronization settings with SPONT mode
Description: One-hour period where the pressure support of spontaneous breath will be manually set.
Study: NCT05626348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate，10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate，10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Injection
Description: Adalimumab Injection，40mg，iH，every two weeks (q2w) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Leflunomide，20mg, po, quaque day (qd) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine，200mg, po, twice per day (bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Study: NCT05108935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suboxone
Description: Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
Study: NCT05250479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness education
Description: 44 primiparous pregnant women will receive mindfulness education
Study: NCT06445920

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT06641947

Intervention type: PROCEDURE
Intervention: Whipple procedure
Description: Typically used for treating pancreatic cancer, particularly tumors located in the head of the pancreas.
Study: NCT06393322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression e-Learning A
Description: Participants in Depression e-Learning A will be provided e-learning about depression, consisting of following components:~1. One multimedia e-learning lesson on depression;~2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson.~1. One multimedia e-learning lesson on depression; 2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression e-Learning B
Description: Participants in Depression e-Learning B will be provided e-learning about depression, consisting of following components:~1. One multimedia e-learning lesson on depression;~2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson.~1. One multimedia e-learning lesson on depression; 2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson.
Study: NCT06641505

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guiding rehydration
Description: Preoperative fluid rehydration was performed according to 421 fluid rehydration principles
Study: NCT05108935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavyret
Description: Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
Study: NCT05682963

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Square Step Exercises Program
Description: Intervention description: patient will be treated for eight weeks, two days a week, one session a day, and total 16 session. Each session will be 45 minute.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program
Description: Frenkel's coordination exercises will be applied as a home program for 8 weeks, 2 days a week, with each exercise session 15-30 minutes excluding rest periods.
Study: NCT05545436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )
Description: Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine ) Drug: Camrelizumab 200mg Drug: oxaliplatin 130 mg/m2 Drug: Teggio 40 mg/m2 Drug: oxaliplatin 130 mg/m2 Drug: capecitabine 1000 mg/m2 Q3W for 3 cycles. Radical surgery was performed 3 weeks after the last neoadjuvant treatment.
Study: NCT05919901

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HPV Vaccine Communication Strategy
Description: The intervention will include health promotions materials and provision of HPV vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HPV Vaccine Communication Strategy
Description: The intervention will include health promotions materials and provision of HPV vaccine
Study: NCT06641505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guiding rehydration
Description: Preoperative fluid rehydration was performed according to 421 fluid rehydration principles
Study: NCT06160180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Submucosal application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Submucosal application
Study: NCT06643689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: Tranilast is an anti-allergic agent that is hypothesized to prevent stricture formation in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive 100 mg orally three times a day for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Prednisone is a corticosteroid used to reduce inflammation and prevent stricture in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive an oral dose of 30 mg once daily for 8 weeks, with a gradual tapering of the dosage as follows: Weeks 1-2: 30 mg daily; Weeks 3-4: 25 mg daily; Weeks 5-6: 20 mg daily; Weeks 7-8: 15 mg daily; and then tapering to 10 mg daily in Week 7 and 5 mg daily in Week 8.
Study: NCT06393322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety e-Learning A
Description: Participants in Anxiety e-Learning A will be provided e-learning about anxiety, consisting of following components:~1. One multimedia e-learning lesson on anxiety;~2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety e-Learning B
Description: Participants in Anxiety e-Learning B will be provided e-learning about anxiety, consisting of following components:~1. One multimedia e-learning lesson on anxiety;~2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson.
Study: NCT06259500

Intervention type: OTHER
Intervention: observational
Description: Profiling the function of iPSC derived Arcuate neurons and PBMC derived microglia

Intervention type: OTHER
Intervention: observational
Description: Profiling the function of iPSC derived Arcuate neurons and PBMC derived microglia
Study: NCT05038176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MANUP
Description: Intervention will include diabetes education, diabetes support with a focus on coping techniques (based on John Henryism concepts), physical activity engagement and motivational text messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MANUP
Description: Intervention will include diabetes education, diabetes support with a focus on coping techniques (based on John Henryism concepts), physical activity engagement and motivational text messages.
Study: NCT06355674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding education provided with Lactation Simulation Model
Description: The Lactation Simulation Model (LSM) is a high-fidelity simulator designed for interactive education, which educators can utilize for practical and wearable breastfeeding training. It is wearable like a shirt and is secured onto the chest by passing it over the shoulders and fastening it with a safety belt from the back. This allows the safety belt to be adjusted according to different body types and weights.
Study: NCT06321484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-Induced Memory-like Natural Killer Cells
Description: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells Autologous, cytokine induced memory-like natural killer cells, via intraperitoneal (IP) infusion per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-Induced Memory-like Natural Killer Cells
Description: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells Autologous, cytokine induced memory-like natural killer cells, via intraperitoneal (IP) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin 2
Description: Low dose subcutaneous IL-2 will be administered every other day for 5 doses after CIML NK cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin 2
Description: Low dose subcutaneous IL-2 will be administered every other day for 5 doses after CIML NK cell infusion
Study: NCT04644497

Intervention type: PROCEDURE
Intervention: ACL-reconstruction
Description: Surgery technique in skeletally immature patients

Intervention type: PROCEDURE
Intervention: ACL-reconstruction
Description: Surgery technique in skeletally immature patients
Study: NCT05233254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal Hollowing exercise
Description: Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out. Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out.
Study: NCT04631471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibudilast
Description: Increasing dose of ibudilast from 60mg/6 capsules per day to 100mg/10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical decompressive surgery
Description: Surgical decompression of degenerate cervical myelopathy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cervical decompressive surgery
Description: Surgical decompression of degenerate cervical myelopathy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Increasing dose of matching placebo from 6 capsules per day to 10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
Study: NCT05482568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316
Description: Drug: SHR-A1811 \& Pyrotinib~SHR-A1811： intravenous Pyrotinib：oral~Drug: SHR-A1811 \& SHR-1316~SHR-A1811： intravenous SHR-1316： intravenous
Study: NCT05167526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8731
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8731
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8731
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8731
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASP8731 Matching Placebo
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASP8731 Matching Placebo
Description: Oral
Study: NCT05634057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anisodamine hydrobromide combined with heparin
Description: The anisodamine hydrobromide combined with heparin treatment group is on the basis of conventional treatment.
Study: NCT06178705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helpful Parenting Program Intervention
Description: 8-10 sessions with 60 minutes duration once in a week will be conducted with the parents in group and one-on-one setting. Helpful parenting program would be based on social learning theory, behavior modification and couple counseling. The program will be used as an intervention strategy with parents to built insight about their child's emotional \& behavioral issues. Different strategies to teach parenting skills will also be used as an intervention. Further more, this program will target parents' psychological distress and couples' problematic conflicts regarding parenting
Study: NCT04503291

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metal stent placement
Description: Non-covered biliary metal stents are placed by endoscopy. The distal ends of metal stents are located above the major ampulla in the common bile duct or below the major ampulla in the duodenum.
Study: NCT06337643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVX01
Description: Pneumococcal Vaccine Candidate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVX01
Description: Pneumococcal Vaccine Candidate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVX01
Description: Pneumococcal Vaccine Candidate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVX01
Description: Pneumococcal Vaccine Candidate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVX01
Description: Pneumococcal Vaccine Candidate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVX01 Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVX01 Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVX01 Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVX01 Placebo
Description: Placebo
Study: NCT05330442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Description: The WET protocol for primary care settings consists of six, 30-minute sessions. The first session consists of psychoeducation of PTSD and treatment rationale. Written narratives are conducted in sessions 2-6, following specific writing instructions and 20 minutes of writing in each session.
Study: NCT05329688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: novel nutrition program
Description: Give nutrition health education every two weeks and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: novel nutrition program
Description: Give nutrition health education every two weeks and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease.
Study: NCT05203133

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Balance
Description: Energy balance phase to elicit weight-maintenance

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Deficit
Description: Energy deficit phase to elicit weight-loss

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Baseline Assessment
Description: Free-living assessment of energy status
Study: NCT05416931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACD440 Gel 14mg/g
Description: Topical application to painful area

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Topical application to painful area
Study: NCT05182502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel
Description: Subjects will receive 3 monthly treatments with the Tixel device to treat the signs of photodamage
Study: NCT05583409

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT+Osimertinib
Description: Received SBRT after three months of Osimertinib treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib 80 MG
Description: Osimertinib 80mg, po, Qd
Study: NCT06447753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct pulp capping
Description: after caries excavation, the pulp will be inspected visually. If bleeding present, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 6 min if required. Cases in which bleeding will not stop within 6 minutes will be excluded from the study and further managed by RCT. The exposed pulp will be capped with MTA which will be freshly mixed according to manufacturer's instructions and placed in thickness of 2 to 3 mm over the pulp exposure site using an amalgam carrier following which the cavity floor will be dabbed with moist sterile cotton pellet to ensure the setting of MTA, followed by application of a layer of light-cure RMGIC over MTA and light-curing for 20s. Then tooth will be restored using composite resin following etch and rinse technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete Pulpotomy
Description: exposed pulp tissue will be amputated using fresh sterile large round diamond bur in a high-speed hand-piece under water coolant 28to the level of canal orifices. The pulp wound will be irrigated with 3% NaOCl. For hemostasis, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 6 min if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved within 6 minutes. After hemostasis, ProRoot MTA will be placed in thickness of 2 to 3 mm over the pulp exposure site using an amalgam carrier. After placement, the cavity floor will be dabbed with moist sterile cotton pellet to ensure the setting of MTA, followed by application of a layer of light-cure RMGIC over MTA and light-curing for 20s. The tooth then will be restored using composite resin following etch and rinse technique.
Study: NCT06200376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered intraperitoneally twice a week.
Study: NCT05765032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921；
Description: Drug: SHR-A1921 administered as an IV infusion Drug: Adebrelimab administered as an IV infusion Drug: Carboplatin administered as an IV infusion Drug: Cisplatin administered as an IV infusion Drug: Bevacizumab administered as an IV infusion